Share on LinkedInShare on LinkedIn

ARTICLE · 11 AUGUST 2015

Lumigan Patents Upheld By Unexpected Results

In Allergan, Inc. v. Sandoz, Inc., the Federal Circuit affirmed the district court decision that upheld the validity of the Allergan patents relating to Lumigan® 0.01% glaucoma eye drops.

United StatesIntellectual Property

In Allergan, Inc. v. Sandoz, Inc., the Federal Circuit affirmed the district court decision that upheld the validity of the Allergan patents relating to Lumigan® 0.01% glaucoma eye drops. This decision shows that it is still possible to defend a patent to a pharmaceutical formulation, at least when it is associated with truly unexpected results.

The Lumigan® Products

As described in the Federal Circuit decision, Lumigan® 0.01% is an improvement over Lumigan® 0.03%, which was approved in 2001 for the treatment of open angle glaucoma and ocular hypertension. Lumigan® 0.03% includes 0.03% by weight of bimatoprost and 50 parts per million ("ppm") benzalkonium chloride ("BAK"). In contrast, Lumigan® 0.01% includes 0.01% bimatoprost and 200 ppm BAK.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from